Document Detail


Dolutegravir, abacavir and lamivudine as HIV therapy.
MedLine Citation:
PMID:  24754315     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Introduction: Antiretroviral therapy has evolved dramatically and more potent, safer and convenient drugs have replaced former compounds. Dolutegravir (DTG) is the most recently approved integrase inhibitor. It displays attractive properties such as one pill once daily (QD) dosing, high barrier to resistance and clean safety profile. Moreover, it is planned to be marketed, co-formulated with abacavir (ABC) and lamivudine (3TC) as a single-tablet regimen (STR). The availability of this QD single pill represents a significant step further for a large number of HIV-infected persons. Areas covered: Updated summary of evidence-based information on efficacy and safety of DTG along with ABC and 3TC. All information available on antiretrovirals in the most advanced stages of clinical development reported in peer-reviewed journals or at international meetings has been reviewed. Expert opinion: The combination of DTG, ABC and 3TC displays a high efficacy, superior to many other antiretroviral combinations, including other convenient STR. The good safety profile, low potential for drug interactions and high resistance barrier of DTG- ABC-3TC are unique features than make this co-formulation the preferred choice as HIV therapy in multiple clinical scenarios, including most treatment-naïve and treatment-experienced patients, as part of switch strategies, and in patients with underlying serious medical conditions such as kidney abnormalities, liver disease, metabolic disturbances or neuropsychiatric conditions.
Authors:
Jose Vicente Fernandez-Montero; Pablo Barreiro; Pablo Labarga; Carmen De Mendoza; Vicente Soriano
Related Documents :
23155105 - An audit of partner notification for syphilis and hiv.
22458755 - Economic burden of hepatitis c-associated diseases: europe, asia pacific, and the ameri...
24170615 - Interferon-free regimens for hepatitis c: combine and conquer.
7974675 - Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immu...
6829985 - Immunologic studies of human schistosomiasis. ii. interrelationship of serum and asciti...
9704945 - Optimizing the delivery of hiv counseling and testing services: the uganda experience u...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  15     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2014 May 
Date Detail:
Created Date:  2014-04-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1051-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmita...
Next Document:  The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistan...